IGC Pharma Inc (IGC) News

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

- Mouse Studies Demonstrate Significant Reduction in Amyloid Plaque: 78% in Cortex and 85% in Hippocampus - IGC Pharma, Inc. (NYSE American: IGC...

IGC Reports Financial Results for Fiscal Year Ended March 31, 2024

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, has announced its financial results for...

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be...

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

-- Study Deepens Understanding of Treatments for Alzheimer’s Patients, Enabling More Effective Treatments -- IGC Pharma, Inc. (NYSE American:...

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

-- Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's -- IGC Pharma, Inc (NYSE American: IGC) ("IGC" or the...

Form SC 13D - General statement of acquisition of beneficial ownership

IGC Pharma to Attend BIO International Convention 2024

IGC Pharma, Inc (NYSE American: IGC) (“IGC” or the “Company”), today announced that the Company will be participating in the BIO International...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

- Study Achieves Secondary End Point: Demonstrates Clinical Reduction, approaching statistical significance, at Week Two, in Agitation in...

IGC Pharma Adds Advisor in Artificial Intelligence

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in...

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a $3 million strategic investment from funds managed by Bradbury...

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

- Interim Data: Study Achieves Primary End Point Demonstrating Clinical and Statistically Significant Reductions Compared to Placebo in Agitation...

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced that Ram Mukunda, CEO, and Claudia Grimaldi, Vice...

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an...